6-8 February 2019 Prague
![]() |
![]() |
![]() |
![]() |
26-P | THE EFFECT OF ANTI-VON WILLEBRAND FACTOR IMMUNOGLOBULIN ON ASSAYS OF VON WILLEBRAND FACTOR: CASE REPORTS | Annette Bowyer | ![]() |
![]() |
|||
27-P | THE EFFECT OF EMICIZUMAB ON ASSAYS OF FACTOR VIII ACTIVITY IN SEVERE HAEMOPHILIA A PATIENTS AND ARTIFICIALLY SPIKED PLASMA | Annette Bowyer | ![]() |
![]() |
|||
28-P | THE SOCIOECONOMIC BURDEN OF MODERATE AND SEVERE HAEMOPHILIA IN CHINA: A FEASIBILITY STUDY | Antony Martin | ![]() |
![]() |
|||
35-P | MEASURING rFIX-Fc WITH 19 DIFFERENT COMBINATIONS COAGULOMETERS - REAGENTS : A SINGLE CENTER STUDY | Aurélien Lebreton | ![]() |
![]() |
|||
45-P | OVER TWO DECADES OF ORTHOPAEDIC SURGERY IN PATIENTS WITH INHIBITORS QUANTIFYING THE COMPLICATION OF BLEEDING | Borna Guevel | ![]() |
![]() |
|||
59-P | ASSESSMENT OF CLOTTING ACTIVITY OF RECOMBINANT FIXFC FUSION PROTEIN IN FRENCH HAEMOSTASIS LABORATORIES | Caroline MARTINEZ | ![]() |
![]() |
|||
62-P | USING PATIENT-LEVEL SIMULATION TO MODEL PATIENT-CENTRIC OUTCOMES IN THE ADVENT OF GENE THERAPY IN SEVERE HAEMOPHILIA A | Charlotte CAMP | ![]() |
![]() |
|||
64-P | THE ADVANCE STUDY: A LONGITUDINAL STUDY OF AGE-RELATED COMORBIDITIES IN PEOPLE WITH HAEMOPHILIA BASELINE INTERIM RESULTS AFTER COMPLETED INCLUSION | Christian Qvigstad | ![]() |
![]() |
|||
65-P | CLINICAL EFFICACY OF DIFFERENT TREATMENT OPTIONS FOR HAEMOPHILIA: PITFALLS OF COMPARING ANNUAL BLEEDING RATES | Christine Keipert | ![]() |
![]() |
|||
68-P | A SIMPLE FUNCTIONAL MOBILITY ASSESSMENT TOOL FOR USE IN CLINICAL PRACTICE OR REAL-LIFE STUDIES WITH HEMOPHILIA PATIENTS: STEP 1, DEVELOPMENT OF THE QUESTIONNAIRE (FRENCH VERSION) | Corinne GANDOSSI | ![]() |
![]() |
|||
79-P | IMPACT OF ACUTE AND CHRONIC PAIN ON THE EQ-5D: INSIGHTS FROM THE PROBE STUDY | Declan Noone | ![]() |
![]() |
|||
80-P | PREDICTORS FOR ACUTE AND CHRONIC PAIN IN PATIENTS WITH SEVERE HAEMOPHILIA IN THE PROBE COHORT | Declan Noone | ![]() |
![]() |
|||
86-P | THE WFH WORLD BLEEDING DISORDERS REGISTRY | Mayss Naccache | ![]() |
![]() |
|||
111-P | THE WORKING GROUP SETTING UP THE EAHAD PSYCHOSOCIAL COMMITTEE | Lotte Haverman | ![]() |
![]() |
|||
113-P | TOWARDS EVALUATION OF HEMOPHILIA THERAPIES IN THE NETHERLANDS: A NATIONWIDE PATIENT REGISTRY AND DIGITAL INFUSION LOG. | Geertje Goedhart | ![]() |
![]() |
|||
122-P | TELEMEDICINE AND ITS TOOLS TO IMPROVE REHABILITATION IN HEMOPHILIA | Valentina Begnozzi | ![]() |
![]() |
|||
125-P | CORRECTING HEMOPHILIA A USING HUMAN FVIII PRODUCED IN VIVO BY AFIBROMER SHIELDED ENGINEERED ALLOGENEIC CELLS | David Peritt | ![]() |
![]() |
|||
126-P | MONITORING OF EMICIZUMAB (ACE910): COMPARISON BETWEEN CLOTTING AND CHROMOGENIC ASSAY | Halet Trkantoz | ![]() |
![]() |
|||
151-P | Using individual pharmacokinetic parameters on octocog alfa to predict individual pharmacokinetic parameters on efmoroctocog alfa in persons with hemophilia A | Jacky Yu | ![]() |
![]() |
|||
154-P | PROBLEM JOINT A MORE PATIENT RELEVANT DEFINITION FOR JOINT MORBIDITY IN HAEMOPHILIA | Tom BURKE | ![]() |
![]() |
|||
168-P | COMPARISON OF PATIENT EXPERIENCE (PE) AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PEOPLE WITH SEVERE FACTOR IX DEFICIENCY BEFORE AND AFTER AN EN-MASSE SWITCH TO AN EXTENDED HALF-LIFE (EHL) FACTOR IX (FIX) CONCENTRATE. | Kate Johnston | ![]() |
![]() |
|||
169-P | THROMBOPROPHYLAXIS AND SURGICAL OUTCOMES IN PEOPLE WITH HAEMOPHILIA UNDERGOING ORTHOPAEDIC SURGERY: ESTABLISHING A LOCAL STANDARD OF CARE | Kate Johnston | ![]() |
![]() |
|||
194-P | ANALYSIS OF THE EDUCATION AND WORK SITUATIONS IN ADULT PATIENTS WITH HEMOPHILIA. | Maria Sol Cruz | ![]() |
![]() |
|||
195-P | UPDATE TO THE MANUAL ON DENTAL MANAGEMENT IN HEMOPHILIA AND VON WILLEBRAND PATIENTS | Maria Sol Cruz | ![]() |
![]() |
|||
204-P | PART-TIME EMPLOYMENT AND EARLY RETIREMENT IN PEOPLE WITH SEVERE HAEMOPHILIA: INSIGHTS FROM THE PROBE STUDY | Mark Skinner | ![]() |
![]() |
|||
207-P | IN THE PRESENCE OF EMICIZUMAB, FACTOR VIIA ACTIVATION OF FACTOR IX CONTRIBUTES TO FACTOR XA GENERATION. | Maureane Hoffman | ![]() |
![]() |
|||
213-P | INSIGHTS INTO THE EVOLUTION OF HAEMOPHILIAC ARTHROPATHY: THE IRISH PERSONALISED APPROACH TO THE TREATMENT OF HAEMOPHILIA (IPATH) STUDY. | MICHELLE LAVIN | ![]() |
![]() |
|||
220-P | USE OF VON WILLEBRAND FACTOR CONCENTRATE IN INHERITED VON WILLEBRAND DISEASE. HOW OFTEN IS IT USEFUL TO ADD FACTOR VIII ? | Nicolas Drillaud | ![]() |
![]() |
|||
235-P | EVALUATION OF HEMORRHAGE RISK IN HAEMOPHILIAC A PATIENTS WITH AND WITHOUT INHIBITOR BY MEANS OF CALIBRATED AUTOMATIC THROMBOGRAM (CAT) | Laura Tomás Menor | ![]() |
![]() |
|||
236-P | EXPOSURE DEGREE TO RECOMBINANT FACTORS AND BLEEDING EPISODES IN PATIENTS WITH SEVERE HAEMOPHILIA A IN A SINGLE HAEMOPHILIA CENTRE | LAURA TOMÁS | ![]() |
![]() |
|||
237-P | MUSCULOSKELETAL ULTRASOUND EVALUATION OF EXTRARTICULAR EFFUSIONS IN HAEMOPHILIC PEDIATRIC PATIENTS | Alejandra Patricia Nally | ![]() |
![]() |
|||
241-P | DILUTIONAL LINEARITY DEMONSTRATED OVER THE WHOLE MEASURING RANGE FOR TWO EXTENDED HALF LIFE RECOMBINANT FACTOR IX (EHL-RFIX) PRODUCTS WITH A CHROMOGENIC FACTOR IX KIT. | Per Rosen | ![]() |
![]() |
|||
249-P | TREATMENT PATTERNS, DETERMINANTS AND OUTCOMES OF HEMOPHILIA: RESULTS FROM A MULTINATIONAL SURVEY | Pronabesh DasMahapatra | ![]() |
![]() |
|||
257-P | AN INTRODUCTION TO CVESS: THE COST OF VON WILLEBRAND DISEASE IN EUROPE- A SOCIOECONOMIC STUDY | Rosa Willock | ![]() |
![]() |
|||
267-P | GOING DIGITAL WITH CLINICAL TREATMENT PLANS | Sarah Mangles | ![]() |
![]() |
|||
268-P | THE CARES STUDY FOCUS GROUPS- HAEMOPHILIA CARRIERS EXPERIENCE STUDY: LIFE CHOICES, PSYCHOSOCIAL NEEDS AND PARENTING | Sarah Mangles | ![]() |
![]() |
|||
269-P | RESOURCE USE AND COSTS OF HEMOPHILIA A PATIENTS IN THE NETHERLANDS | Tam VO | ![]() |
![]() |
|||
275-P | CONGENITAL FACTOR XIII DEFICIENCY : DESCRIPTION OF THE FRENCH COHORT FROM THE FRANCECOAG NETWORK. | Séverine Bouttefroy | ![]() |
![]() |
|||
284-P | REVIEW OF HAEMOPHILIA CARE IN INDIA | Stefan Bosbach | ![]() |
![]() |
|||
285-P | THROMBIN GENERATION ASSAY TO GUIDE REPLACEMENT THERAPY IN PATIENTS WITH FACTOR XI DEFICIENCY UNDERGOING ELECTIVE SURGERY | Stéphanie Désage | ![]() |
![]() |
|||
293-P | ASSOCIATED IMPACT OF TREATMENT ADHERENCE ON HEALTH-RELATED QUALITY OF LIFE AND WORK IMPAIRMENT IN SEVERE HAEMOPHILIA A | Charlotte CAMP | ![]() |
![]() |
|||
294-P | AN INTRODUCTION TO THE COST OF HAEMOPHILIA ACROSS EUROPE - A SOCIOECONOMIC SURVEY (CHESS): PAEDIATRICS STUDY | Tom Burke | ![]() |
![]() |
|||
295-P | KEY FINDINGS FROM AN EXPERT VALIDATION WORKSHOP TO ESTABLISH AN APPROPRIATE MODELLING FRAMEWORK IN SEVERE HAEMOPHILIA A | Charlotte CAMP | ![]() |
![]() |
|||
296-P | USE OF PHARMACOKINETICS-PHARMACODYNAMICS MODELING AND SIMULATION TO SUPPORT EARLY PHASE DOSE SELECTION FOR PF-06741086, AN ANTI-TFPI MONOCLONAL ANTIBODY | Aileen Echeverry | ![]() |
![]() |
|||
298-P | EXERGAMES FOR HOME REHABILITATION IN CHILDREN WITH HEMOPHILIA | Valentina Begnozzi | ![]() |
![]() |
|||
300-P | IMPLEMENTATION OF A WEB-BASED PLATFORM FOR JOINT MONITORING IN PATIENTS WITH HAEMOPHILIA IN NHEMO DATABASE | VALERIE HORVAIS | ![]() |
![]() |
|||
302-P | LOW DOZE PROPHYLAXIS THERAPY IN SEVERE PEDIATRIC HEMOPHILIA A PATIENTS | Vijay Shah | ![]() |
![]() |
|||
303-P | AVOIDING ACCUMULATION OF FVIII WHEN TREATING VWD PATIENTS WITH NORMAL BASELINE FVIII LEVELS BY USING A HIGH RATIO VON WILLEBRAND CONCENTRATE | Vincent Hortensius | ![]() |
![]() |
6-8 February 2019 Prague
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|